| Q26782793 | A Gut Odyssey: The Impact of the Microbiota on Clostridium difficile Spore Formation and Germination |
| Q35933501 | A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection |
| Q89485932 | Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation |
| Q92800311 | Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients |
| Q36018083 | Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease |
| Q58568018 | Advances in Molecular Epidemiology of Infectious Diseases: Definitions, Approaches, and Scope of the Field |
| Q97069843 | An ecological framework to understand the efficacy of fecal microbiota transplantation |
| Q41986554 | Antibiotics, gut microbiome, and obesity. |
| Q30410992 | Approaches to studying and manipulating the enteric microbiome to improve autism symptoms |
| Q40721471 | Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand |
| Q47103123 | Back to the future in a petri dish: Origin and impact of resurrected microbes in natural populations |
| Q40081529 | Beyond gut feelings: how the gut microbiota regulates blood pressure. |
| Q97067608 | Bifidobacterium bifidum Suppresses Gut Inflammation Caused by Repeated Antibiotic Disturbance Without Recovering Gut Microbiome Diversity in Mice |
| Q35918566 | Breakthroughs in the treatment and prevention of Clostridium difficile infection |
| Q38764998 | Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. |
| Q47182437 | Characterization of the Stool Microbiome in Hispanic Preschool Children by Weight Status and Time |
| Q41996759 | Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection. |
| Q30239988 | Clostridium difficile infection: Updates in management |
| Q90542250 | Commentary on key aspects of fecal microbiota transplantation in small animal practice |
| Q46311710 | Complementary methodologies to investigate human gut microbiota in host health, working towards integrative systems biology |
| Q89470697 | Considering gut microbiota in treatment of type 2 diabetes mellitus |
| Q41932327 | Control of Clostridium difficile Infection by Defined Microbial Communities. |
| Q47341286 | Cryopreservation of artificial gut microbiota produced with in vitro fermentation technology |
| Q90862879 | Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome |
| Q40339859 | Designing fecal microbiota transplant trials that account for differences in donor stool efficacy |
| Q33824299 | Distinct patterns in the gut microbiota after surgical or medical therapy in obese patients |
| Q55449256 | Does the Internet promote the unregulated use of fecal microbiota transplantation: a potential public health issue? |
| Q64977821 | Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms. |
| Q33839421 | Ephedra-Treated Donor-Derived Gut Microbiota Transplantation Ameliorates High Fat Diet-Induced Obesity in Rats |
| Q40886412 | Establishing a Fecal Microbiota Transplant Service for the Treatment of Clostridium difficile Infection |
| Q38770514 | European consensus conference on faecal microbiota transplantation in clinical practice. |
| Q39113167 | Evolutionary and ecological forces that shape the bacterial communities of the human gut. |
| Q54256498 | Faecal Microbiota Transplantation for Clostridium Difficile - a local perspective. |
| Q47112915 | Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications: A case series |
| Q36919674 | Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders |
| Q64912806 | Fecal Microbial Transplantation and Its Potential Application in Cardiometabolic Syndrome. |
| Q89591198 | Fecal Microbiota Transfer |
| Q42553481 | Fecal Microbiota Transfer 2.0. |
| Q51731616 | Fecal Microbiota Transplantation in Gestating Sows and Neonatal Offspring Alters Lifetime Intestinal Microbiota and Growth in Offspring. |
| Q28084737 | Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond |
| Q36241633 | Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. |
| Q57166529 | Fecal microbiota transplant - a new frontier in inflammatory bowel disease |
| Q39395831 | Fecal microbiota transplantation for recurrent clostridium difficile infection in children. |
| Q35959464 | Fecal microbiota transplantation in children: a brief review |
| Q38909454 | Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail |
| Q33821397 | Fecal microbiota transplantation in metabolic syndrome: History, present and future |
| Q40370832 | Fecal microbiota transplantation to fight Clostridium difficile infections and other intestinal diseases |
| Q26765214 | Fecal microbiota transplantation: in perspective |
| Q40397907 | Fecal microbiota transplantation: indications and perspectives |
| Q93336613 | Fecal transplantation for treatment of inflammatory bowel disease |
| Q35671153 | Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations |
| Q35861517 | From Hype to Hope: The Gut Microbiota in Enteric Infectious Disease |
| Q38958165 | Functional Genomics and Its Bench-to-Bedside Translation Pertaining to the Identified Susceptibility Alleles and Loci in Ankylosing Spondylitis. |
| Q57954149 | GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet, February 2nd 2015 |
| Q36145301 | Gastroenterologist perceptions of faecal microbiota transplantation. |
| Q35917479 | Gastroenvironmental distress: metaphorical antecedents of the gut microbiome |
| Q26776155 | Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection |
| Q44875794 | Genome Editing of Food-Grade Lactobacilli To Develop Therapeutic Probiotics. |
| Q38794312 | Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. |
| Q35765629 | Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and Prebiotic Potential of Polyphenol-Rich Extracts |
| Q39111395 | Gut Microbiota in Obesity and Undernutrition |
| Q28066301 | Gut Microbiota: A Contributing Factor to Obesity |
| Q47135950 | Gut dysbiosis and impairment of immune system homeostasis in perinatally-exposed mice to Bisphenol A precede obese phenotype development. |
| Q99731217 | Gut microbiota and old age: Modulating factors and interventions for healthy longevity |
| Q96230902 | Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer |
| Q35935129 | Gut microbiota, obesity and diabetes. |
| Q33749944 | How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study |
| Q59068503 | How gut microbes are joining the fight against cancer |
| Q36012805 | How to Manipulate the Microbiota: Fecal Microbiota Transplantation |
| Q26795386 | Human microbiome: From the bathroom to the bedside |
| Q35750753 | Humanized microbiota mice as a model of recurrent Clostridium difficile disease |
| Q89531511 | Identification of Clostridioides difficile-Inhibiting Gut Commensals Using Culturomics, Phenotyping, and Combinatorial Community Assembly |
| Q59813006 | Inhibitory Effect of Ursodeoxycholic Acid on Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans |
| Q60949906 | Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease |
| Q40708125 | Long-term microbiota and virome in a Zürich patient after fecal transplantation against Clostridium difficile infection |
| Q89389015 | Management of Primary and Recurrent Clostridium difficile Infection: An Update |
| Q48168386 | Meta-Analysis of Fecal Microbiota and Metabolites in Experimental Colitic Mice during the Inflammatory and Healing Phases |
| Q93133936 | Metagenomic and culturomic analysis of gut microbiota dysbiosis during Clostridium difficile infection |
| Q38781325 | Microbiome and chronic inflammatory bowel diseases |
| Q91975122 | Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential |
| Q46274429 | Microbiota Replacement Therapies: Innovation in Gastrointestinal Care |
| Q52716963 | Microbiota transplantation: concept, methodology and strategy for its modernization. |
| Q90062661 | Microbiota, Microbial Metabolites, and Barrier Function in A Patient with Anorexia Nervosa after Fecal Microbiota Transplantation |
| Q48050303 | Modulating adult neurogenesis through dietary interventions |
| Q38755858 | Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. |
| Q39276552 | Ménage à trois in the human gut: interactions between host, bacteria and phages |
| Q89380138 | New-Onset Microscopic Colitis in an Ulcerative Colitis Patient After Fecal Microbiota Transplantation |
| Q39185571 | Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature |
| Q26745706 | Novel perspectives on therapeutic modulation of the gut microbiota |
| Q37088255 | Obesity and Asthma: Microbiome-Metabolome Interactions |
| Q39154018 | Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension |
| Q88674656 | Pathways and mechanisms linking dietary components to cardiometabolic disease: thinking beyond calories |
| Q92025248 | Patient perception and approval of faecal microbiota transplantation (FMT) as an alternative treatment option for obesity |
| Q53694217 | Pre-colonization with the commensal fungus Candida albicans reduces murine susceptibility to Clostridium difficile infection. |
| Q36945060 | Probiotic lactic acid bacteria - the fledgling cuckoos of the gut? |
| Q36018176 | Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for? |
| Q37199659 | Prolonged transfer of feces from the lean mice modulates gut microbiota in obese mice. |
| Q64100096 | Protocol for the Gut Bugs Trial: a randomised double-blind placebo-controlled trial of gut microbiome transfer for the treatment of obesity in adolescents |
| Q52607694 | Recruitment of feces donors among blood donors: Results from an observational cohort study. |
| Q92089842 | Regulation of Microbiota by Vitamin D Receptor: A Nuclear Weapon in Metabolic Diseases |
| Q35834277 | Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota |
| Q49733575 | Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation |
| Q92435669 | Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications |
| Q33466550 | Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study |
| Q38973619 | Signals from the gut microbiota to distant organs in physiology and disease |
| Q93011594 | Stable Neutralization of a Virulence Factor in Bacteria Using Temperate Phage in the Mammalian Gut |
| Q39457663 | Strategies to increase the efficacy of using gut microbiota for the modulation of obesity. |
| Q90403282 | Targeting the Gut Microbiota to Treat Cachexia |
| Q37371393 | The Gut Microbiome and Its Role in Obesity |
| Q42206776 | The Human Microbiome and the Missing Heritability Problem. |
| Q36751990 | The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease |
| Q55601781 | The Microbiological Memory, an Epigenetic Regulator Governing the Balance Between Good Health and Metabolic Disorders. |
| Q26765740 | The New Era of Treatment for Obesity and Metabolic Disorders: Evidence and Expectations for Gut Microbiome Transplantation |
| Q52315444 | The Role of Gut Microbiota in Obesity and Type 2 and Type 1 Diabetes Mellitus: New Insights into "Old" Diseases. |
| Q58103045 | The gut microbiome participates in transgenerational inheritance of low temperature responses in Drosophila melanogaster |
| Q89767716 | The microbiome and gynaecological cancer development, prevention and therapy |
| Q48138111 | The microbiota-gut-brain axis in obesity |
| Q53736806 | The path towards microbiome-based metabolite treatment. |
| Q39401642 | The remedy within: will the microbiome fulfill its therapeutic promise? |
| Q90376906 | The role of the brain-gut-microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders |
| Q39290620 | The role of the microbiome in cancer development and therapy |
| Q101038709 | The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome |
| Q90146824 | Therapies to modulate gut microbiota: Past, present and future |
| Q28078234 | Treating Obesity and Metabolic Syndrome with Fecal Microbiota Transplantation |
| Q99552007 | Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy |
| Q35980261 | Turning Participatory Microbiome Research into Usable Data: Lessons from the American Gut Project |
| Q39414517 | Update on intestinal microbiota in Crohn's disease 2017: Mechanisms, Clinical application, Adverse reactions and Outlook. |
| Q90918890 | Using bioreactors to study the effects of drugs on the human microbiota |
| Q54207972 | Using bugs as drugs: Microbial ecosystem therapeutics. |
| Q26797301 | Why does obesity promote cancer? Epidemiology, biology, and open questions |
| Q89361606 | [Fecal microbiota transplantation] |
Search more.